{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:14:24Z","timestamp":1788498864090,"version":"build-2803163510"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Med"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40290-026-00631-z","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T09:23:35Z","timestamp":1787045015000},"page":"399-412","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Placebo Response in Randomised Controlled Trials of Systemic Therapies for Cutaneous Lupus Erythematosus: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"40","author":[{"given":"St\u00e9phanie","family":"L\u00e9gar\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Vahey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6300-5341","authenticated-orcid":false,"given":"Juan Gabriel","family":"Ovalles\u2011Bonilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pina","family":"D\u2019Angelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9973-1203","authenticated-orcid":false,"given":"Jasmina","family":"Jankicevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5927-6587","authenticated-orcid":false,"given":"Robert","family":"Bissonnette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"issue":"3","key":"631_CR1","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.abd.2022.09.005","volume":"98","author":"ECSd Vale","year":"2023","unstructured":"Vale ECSd, Garcia LC. Cutaneous lupus erythematosus: a review of etiopathogenic, clinical, diagnostic and therapeutic aspects. An Bras Dermatol. 2023;98(3):355\u201372. https:\/\/doi.org\/10.1016\/j.abd.2022.09.005.","journal-title":"An Bras Dermatol"},{"issue":"3","key":"631_CR2","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1001\/jamadermatol.2013.10393","volume":"150","author":"AB Eastham","year":"2014","unstructured":"Eastham AB, Vleugels RA. Cutaneous lupus erythematosus. JAMA Dermatol. 2014;150(3):344\u2013344. https:\/\/doi.org\/10.1001\/jamadermatol.2013.10393.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"631_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2022-000819","volume":"10","author":"J Hui","year":"2023","unstructured":"Hui J, Shihang Z, Yangyiyi Y, et al. Panoramic view of clinical features of lupus erythematosus: a cross-sectional multicentre study from China. Lupus Sci Med. 2023;10(1):e000819. https:\/\/doi.org\/10.1136\/lupus-2022-000819.","journal-title":"Lupus Sci Med."},{"issue":"4","key":"631_CR4","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/ddg.15049","volume":"21","author":"C G\u00fcnther","year":"2023","unstructured":"G\u00fcnther C, Wenzel J. Lupus erythematosus. JDDG J Dtsch Dermatol Ges. 2023;21(4):426\u201330. https:\/\/doi.org\/10.1111\/ddg.15049.","journal-title":"JDDG J Dtsch Dermatol Ges"},{"issue":"3","key":"631_CR5","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/jdv.14053","volume":"31","author":"A Kuhn","year":"2017","unstructured":"Kuhn A, Aberer E, Bata-Cs\u00f6rg\u0151 Z, et al. S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2017;31(3):389\u2013404. https:\/\/doi.org\/10.1111\/jdv.14053.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"631_CR6","doi-asserted-by":"publisher","first-page":"1373552","DOI":"10.3389\/fmed.2024.1373552","volume":"11","author":"JF Merola","year":"2024","unstructured":"Merola JF, Nyberg F, Franchimont N, Barbey C, Werth VP. Editorial: Cutaneous lupus erythematosus landscape: pathophysiology, unmet needs, and related challenges in clinical practice. What is on the horizon? Front Med. 2024;11:1373552. https:\/\/doi.org\/10.3389\/fmed.2024.1373552.","journal-title":"Front Med"},{"issue":"5","key":"631_CR7","doi-asserted-by":"publisher","first-page":"431","DOI":"10.21037\/atm-20-5048","volume":"9","author":"S Chakka","year":"2021","unstructured":"Chakka S, Krain RL, Concha JSS, Chong BF, Merola JF, Werth VP. The CLASI, a validated tool for the evaluation of skin disease in lupus erythematosus: a narrative review. Ann Transl Med. 2021;9(5):431. https:\/\/doi.org\/10.21037\/atm-20-5048.","journal-title":"Ann Transl Med"},{"issue":"2","key":"631_CR8","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1001\/archdermatol.2010.435","volume":"147","author":"R Klein","year":"2011","unstructured":"Klein R, Moghadam-Kia S, LoMonico J, et al. Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus. Arch Dermatol. 2011;147(2):203\u20138. https:\/\/doi.org\/10.1001\/archdermatol.2010.435.","journal-title":"Arch Dermatol"},{"key":"631_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000529","author":"LN Guo","year":"2021","unstructured":"Guo LN, Perez-Chada LM, Borucki R, Nambudiri VE, Werth VP, Merola JF. Development of a working core outcome set for cutaneous lupus erythematosus: a practical approach to an urgent unmet need. Lupus Sci Med. 2021. https:\/\/doi.org\/10.1136\/lupus-2021-000529.","journal-title":"Lupus Sci Med"},{"key":"631_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2021.106503","volume":"107","author":"K Evans","year":"2021","unstructured":"Evans K, Colloca L, Pecina M, Katz N. What can be done to control the placebo response in clinical trials? A narrative review. Contemp Clin Trials. 2021;107:106503. https:\/\/doi.org\/10.1016\/j.cct.2021.106503.","journal-title":"Contemp Clin Trials"},{"key":"631_CR11","volume-title":"Cochrane handbook for systematic reviews of interventions","year":"2024","unstructured":"Higgins JPTTJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane handbook for systematic reviews of interventions. ed. vol Version 6.5. Cochrane; 2024.","edition":"ed. vol Version"},{"key":"631_CR12","doi-asserted-by":"publisher","unstructured":"Furie R, Van Vollenhoven R, Werth V, et al. Efficacy of BIIB059 on Joint and Skin Manifestations in Participants with Systemic Lupus Erythematosus (SLE): exploratory Analyses of the Phase 2, Randomized, Double-Blind, Placebo-Controlled LILAC Study (Part A). Journal article; Conference proceeding. Arthr. Rheumatol. 2022;74:720\u2010723. https:\/\/doi.org\/10.1002\/art.42355","DOI":"10.1002\/art.42355"},{"issue":"10","key":"631_CR13","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1056\/NEJMoa2118025","volume":"387","author":"RA Furie","year":"2022","unstructured":"Furie RA, Van Vollenhoven RF, Kalunian K, et al. Trial of anti-BDCA2 antibody litifilimab for systemic lupus erythematosus. N Engl J Med. 2022;387(10):894\u2013904. https:\/\/doi.org\/10.1056\/NEJMoa2118025.","journal-title":"N Engl J Med"},{"key":"631_CR14","doi-asserted-by":"publisher","unstructured":"Van Vollenhoven R, Furie R, Werth V, et al. Efficacy of BIIB059 on skin manifestations in participants with systemic lupus erythematosus (sle) in the phase 2 lilac study (part a). Journal article; Conference proceeding. Ann Rheum Dis. 2022;81:323\u2010324. https:\/\/doi.org\/10.1136\/annrheumdis-2022-eular.2072","DOI":"10.1136\/annrheumdis-2022-eular.2072"},{"key":"631_CR15","doi-asserted-by":"publisher","unstructured":"Werth V, Furie R, Kalunian K, et al. Greater reduction in CLASI-a scores achieved with BIIB059 versus placebo independently of disease severity at baseline. Journal article; Conference proceeding. Ann Rheum Dis. 2021;80(SUPPL 1):598\u2010599. https:\/\/doi.org\/10.1136\/annrheumdis-2021-eular.2716","DOI":"10.1136\/annrheumdis-2021-eular.2716"},{"key":"631_CR16","doi-asserted-by":"publisher","unstructured":"Werth V, Van Vollenhoven R, Furie R, et al. Improvements in Skin Manifestations with BIIB059 Measured by CLASI in Participants with Cutaneous Lupus Erythematosus (CLE): exploratory Analyses of the Phase 2, Randomized, Double-Blind, Placebo-Controlled LILAC Study (Part B). Journal article; Conference proceeding. Arthr Rheumatol. 2022;74:723\u2010725. https:\/\/doi.org\/10.1002\/art.42355","DOI":"10.1002\/art.42355"},{"issue":"4","key":"631_CR17","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa2118024","volume":"387","author":"VP Werth","year":"2022","unstructured":"Werth VP, Furie RA, Romero-Diaz J, et al. Trial of anti-BDCA2 antibody litifilimab for cutaneous lupus erythematosus. N Engl J Med. 2022;387(4):321\u20133313. https:\/\/doi.org\/10.1056\/NEJMoa2118024.","journal-title":"N Engl J Med"},{"key":"631_CR18","doi-asserted-by":"publisher","unstructured":"Werth V, Furie R, Morand E, et al. Early and Sustained Reduction in Severity of Skin Disease with Anifrolumab Treatment in Patients with Active SLE Measured by the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI): pooled Data from 2 Phase 3 Studies. Journal article; Conference proceeding. Arthr Rheumatol 2020;72(SUPPL 10):1975\u20101978. https:\/\/doi.org\/10.1002\/art.41538","DOI":"10.1002\/art.41538"},{"issue":"10155","key":"631_CR19","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/s0140-6736(18)32167-6","volume":"392","author":"RF van Vollenhoven","year":"2018","unstructured":"van Vollenhoven RF, Hahn BH, Tsokos GC, et al. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. Lancet. 2018;392(10155):1330\u20139. https:\/\/doi.org\/10.1016\/s0140-6736(18)32167-6.","journal-title":"Lancet"},{"key":"631_CR20","doi-asserted-by":"publisher","unstructured":"Werth V, Hahn B, Tsokos G, et al. Cutaneous lupus erythematosus disease area & severity index (CLASI) demonstrates thresholds for detection of treatment response in a phase-2, placebo-controlled trial of ustekinumab in SLE. Journal article; Conference proceeding. Arthr Rheumatol 2019;71:1489\u20101490. https:\/\/doi.org\/10.1002\/art.41108","DOI":"10.1002\/art.41108"},{"issue":"5","key":"631_CR21","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1002\/art.40052","volume":"69","author":"VP Werth","year":"2017","unstructured":"Werth VP, Fiorentino D, Sullivan BA, et al. Brief report: pharmacodynamics, safety, and clinical efficacy of AMG 811, a human anti\u2013interferon-\u03b3 antibody, in patients with discoid lupus erythematosus. Arthritis Rheum. 2017;69(5):1028\u201334. https:\/\/doi.org\/10.1002\/art.40052.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"631_CR22","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1136\/annrheumdis-2015-208562","volume":"75","author":"M Khamashta","year":"2016","unstructured":"Khamashta M, Merrill JT, Werth VP, et al. Sifalimumab, an anti-interferon-\u03b1 monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75(11):1909\u201316. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208562.","journal-title":"Ann Rheum Dis"},{"key":"631_CR23","doi-asserted-by":"publisher","unstructured":"Merrill JT, Furie R, Werth VP, et al. The effect of anifrolumab on cutaneous manifestations and arthritis in moderate to severe systemic lupus erythematosus (SLE) using categorical SLEDAI-2K responses and continuous measures of activity as outcome measures. Journal article; Conference proceeding. Arthr Rheumatol2016;68:2569\u20102570. https:\/\/doi.org\/10.1002\/art.39977","DOI":"10.1002\/art.39977"},{"key":"631_CR24","doi-asserted-by":"crossref","unstructured":"Furie R, Merrill J, Werth V, et al. Anifrolumab, an anti-interferon-alpha receptor monoclonal antibody, in moderate to severe systemic lupus erythematosus (SLE). Journal article; Conference proceeding. Clin Exp Rheumatol. 2016;34(4):S4.","DOI":"10.1136\/annrheumdis-2016-eular.3919"},{"issue":"4","key":"631_CR25","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/art.40018","volume":"69","author":"N Yokogawa","year":"2017","unstructured":"Yokogawa N, Eto H, Tanikawa A, et al. Effects of hydroxychloroquine in patients with cutaneous lupus erythematosus: a multicenter, double-blind, randomized, parallel-group trial. Arthritis Rheum. 2017;69(4):791\u20139. https:\/\/doi.org\/10.1002\/art.40018.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"631_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2016-000180","volume":"3","author":"R Furie","year":"2016","unstructured":"Furie R, Mitrane M, Zhao E, Das M, Li D, Becker PM. Efficacy and tolerability of repository corticotropin injection in patients with persistently active SLE: results of a phase 4, randomised, controlled pilot study. Lupus Sci Med. 2016;3(1):e000180. https:\/\/doi.org\/10.1136\/lupus-2016-000180.","journal-title":"Lupus Sci Med"},{"issue":"3","key":"631_CR27","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1172\/JCI124466","volume":"129","author":"R Furie","year":"2019","unstructured":"Furie R, Werth VP, Merola JF, et al. Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus. J Clin Invest. 2019;129(3):1359\u201371. https:\/\/doi.org\/10.1172\/JCI124466.","journal-title":"J Clin Invest"},{"issue":"1","key":"631_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000581","volume":"9","author":"RA Furie","year":"2022","unstructured":"Furie RA, Hough DR, Gaudy A, et al. Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study. Lupus Sci Med. 2022;9(1):e000581. https:\/\/doi.org\/10.1136\/lupus-2021-000581.","journal-title":"Lupus Sci Med"},{"key":"631_CR29","unstructured":"NCT02265744. A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus. National Library of Medicine (US). https:\/\/clinicaltrials.gov\/study\/NCT02265744"},{"key":"631_CR30","unstructured":"NCT02437890. A Phase II Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-range Finding Study to Evaluate the Safety and Efficacy of ALX-0061 Administered Subcutaneously in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus. National Library of Medicine (US). https:\/\/clinicaltrials.gov\/study\/NCT02437890"},{"issue":"3","key":"631_CR31","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1912196","volume":"382","author":"EF Morand","year":"2020","unstructured":"Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382(3):211\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1912196.","journal-title":"N Engl J Med"},{"issue":"4","key":"631_CR32","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","volume":"1","author":"RA Furie","year":"2019","unstructured":"Furie RA, Morand EF, Bruce IN, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol. 2019;1(4):e208\u201319. https:\/\/doi.org\/10.1016\/S2665-9913(19)30076-1.","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"631_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23361-z","volume":"12","author":"SA Hasni","year":"2021","unstructured":"Hasni SA, Gupta S, Davis M, et al. Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus. Nat Commun. 2021;12(1):3391. https:\/\/doi.org\/10.1038\/s41467-021-23361-z.","journal-title":"Nat Commun"},{"key":"631_CR34","unstructured":"NCT02554019. A Prospective, Double-blind, Randomized, Placebo-controlled, Repeated Dose, Multicentre Phase IIa Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus. National Library of Medicine (US). https:\/\/clinicaltrials.gov\/study\/NCT02554019"},{"issue":"1","key":"631_CR35","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2023-001113","volume":"11","author":"DJ Burge","year":"2024","unstructured":"Burge DJ, Werth VP, Boackle SA, Posada J. Evaluation of RNase therapy in systemic lupus erythematosus: a randomised phase 2a clinical trial of RSLV-132. Lupus Sci Med. 2024;11(1):e001113. https:\/\/doi.org\/10.1136\/lupus-2023-001113.","journal-title":"Lupus Sci Med"},{"key":"631_CR36","unstructured":"NCT02665364. A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFN\u03b1-Kinoid in Adult Subjects With Systemic Lupus Erythematosus. National Library of Medicine (US). https:\/\/clinicaltrials.gov\/study\/NCT02665364"},{"issue":"3","key":"631_CR37","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1136\/annrheumdis-2019-216379","volume":"79","author":"FA Houssiau","year":"2020","unstructured":"Houssiau FA, Thanou A, Mazur M, et al. IFN-\u03b1 kinoid in systemic lupus erythematosus: results from a phase IIb, randomised, placebo-controlled study. Ann Rheum Dis. 2020;79(3):347\u201355. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216379.","journal-title":"Ann Rheum Dis"},{"issue":"10143","key":"631_CR38","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/s0140-6736(18)31363-1","volume":"392","author":"DJ Wallace","year":"2018","unstructured":"Wallace DJ, Furie RA, Tanaka Y, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392(10143):222\u201331. https:\/\/doi.org\/10.1016\/s0140-6736(18)31363-1.","journal-title":"Lancet"},{"issue":"11","key":"631_CR39","doi-asserted-by":"publisher","first-page":"5397","DOI":"10.1093\/rheumatology\/keab381","volume":"60","author":"RA Furie","year":"2021","unstructured":"Furie RA, Bruce IN, D\u00f6rner T, et al. Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. Rheumatology (Oxford). 2021;60(11):5397\u2013407. https:\/\/doi.org\/10.1093\/rheumatology\/keab381. (Journal article).","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"631_CR40","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1002\/art.41811","volume":"73","author":"D Isenberg","year":"2021","unstructured":"Isenberg D, Furie R, Jones NS, et al. Efficacy, safety, and pharmacodynamic effects of the Bruton\u2019s tyrosine kinase inhibitor fenebrutinib (GDC-0853) in systemic lupus erythematosus: results of a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2021;73(10):1835\u201346. https:\/\/doi.org\/10.1002\/art.41811.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"631_CR41","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s40744-020-00236-1","volume":"7","author":"AD Askanase","year":"2020","unstructured":"Askanase AD, Zhao E, Zhu J, Bilyk R, Furie RA. Repository corticotropin injection for persistently active systemic lupus erythematosus: results from a phase 4, multicenter, randomized, double-blind, placebo-controlled trial. Rheumatol Ther. 2020;7(4):893\u2013908. https:\/\/doi.org\/10.1007\/s40744-020-00236-1.","journal-title":"Rheumatol Ther"},{"key":"631_CR42","doi-asserted-by":"publisher","unstructured":"Bruce I, Nami A, Schwetje E, et al. PK\/PD, safety and exploratory efficacy of subcutaneous anifrolumab in SLE: a phase-ii study in interferon type i high patients with active skin disease. Journal article; Conference proceeding. Arthr Rheumatol. 2019;71:4545\u20104548. https:\/\/doi.org\/10.1002\/art.41108","DOI":"10.1002\/art.41108"},{"issue":"2","key":"631_CR43","doi-asserted-by":"publisher","first-page":"e101","DOI":"10.1016\/S2665-9913(20)30342-8","volume":"3","author":"IN Bruce","year":"2021","unstructured":"Bruce IN, Nami A, Schwetje E, et al. Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Rheumatol. 2021;3(2):e101\u201310. https:\/\/doi.org\/10.1016\/S2665-9913(20)30342-8.","journal-title":"Lancet Rheumatol"},{"issue":"6","key":"631_CR44","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1093\/rheumatology\/keab685","volume":"61","author":"VP Werth","year":"2022","unstructured":"Werth VP, Fleischmann R, Robern M, et al. Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study. Rheumatology (Oxford). 2022;61(6):2413\u201323. https:\/\/doi.org\/10.1093\/rheumatology\/keab685.","journal-title":"Rheumatology (Oxford)"},{"key":"631_CR45","unstructured":"NCT03134222. A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib and GS-9876 in Female Subjects With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE). National Library of Medicine (US). https:\/\/clinicaltrials.gov\/study\/NCT03134222"},{"issue":"11","key":"631_CR46","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1056\/NEJMoa2106535","volume":"386","author":"JT Merrill","year":"2022","unstructured":"Merrill JT, Werth VP, Furie R, et al. Phase 2 trial of iberdomide in systemic lupus erythematosus. N Engl J Med. 2022;386(11):1034\u201345. https:\/\/doi.org\/10.1056\/NEJMoa2106535.","journal-title":"N Engl J Med"},{"key":"631_CR47","doi-asserted-by":"publisher","unstructured":"Werth V, Merrill J, Furie R, et al. Effect of iberdomide on cutaneous manifestations in systemic lupus erythematosus: results of a 24-week, placebo-controlled, phase 2 study. Journal article; Conference proceeding. Ann Rheum Dis. 2021;80(1):76\u201077. https:\/\/doi.org\/10.1136\/annrheumdis-2021-eular.2181","DOI":"10.1136\/annrheumdis-2021-eular.2181"},{"issue":"2","key":"631_CR48","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/art.42391","volume":"75","author":"E Morand","year":"2023","unstructured":"Morand E, Pike M, Merrill JT, et al. Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2023;75(2):242\u201352. https:\/\/doi.org\/10.1002\/art.42391.","journal-title":"Arthritis Rheumatol"},{"key":"631_CR49","unstructured":"NCT03371251. A Randomized Double-Blind Phase 1b\/2 Combined Staggered Multiple Dose Escalation Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care. National Library of Medicine (US). https:\/\/clinicaltrials.gov\/study\/NCT03371251"},{"issue":"11","key":"631_CR50","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1136\/ard-2022-222858","volume":"81","author":"RF van Vollenhoven","year":"2022","unstructured":"van Vollenhoven RF, Kalunian KC, D\u00f6rner T, et al. Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus. Ann Rheum Dis. 2022;81(11):1556\u201363. https:\/\/doi.org\/10.1136\/ard-2022-222858.","journal-title":"Ann Rheum Dis"},{"key":"631_CR51","unstructured":"NCT03616912. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus. National Library of Medicine (US). https:\/\/clinicaltrials.gov\/study\/NCT03616912"},{"key":"631_CR52","unstructured":"NCT03616964. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus. National Library of Medicine (US). https:\/\/clinicaltrials.gov\/study\/NCT03616964"},{"issue":"1","key":"631_CR53","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2023-001112","volume":"11","author":"SRP McDonnell","year":"2024","unstructured":"McDonnell SRP, Nguyen VA, Walton NM, et al. Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease. Lupus Sci Med. 2024;11(1):e001112. https:\/\/doi.org\/10.1136\/lupus-2023-001112.","journal-title":"Lupus Sci Med"},{"key":"631_CR54","unstructured":"NCT04680637. A Phase 2b Dose Ranging Study to Evaluate the Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus With Inadequate Response to Standard of Care Therapy. National Library of Medicine (US). https:\/\/clinicaltrials.gov\/study\/NCT04680637"},{"key":"631_CR55","unstructured":"NCT04781816. Randomized, Double-blind, Placebo Controlled, Proof of Concept Study Assessing the Efficacy and Safety of the RIPK1-inhibitor SAR443122 in Patients With Moderate to Severe Subacute or Discoid\/Chronic Cutaneous Lupus Erythematosus. National Library of Medicine (US). https:\/\/clinicaltrials.gov\/study\/NCT04781816"},{"issue":"1","key":"631_CR56","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/schbul\/sbx192","volume":"45","author":"D Fraguas","year":"2019","unstructured":"Fraguas D, D\u00edaz-Caneja CM, Pina-Camacho L, Umbricht D, Arango C. Predictors of placebo response in pharmacological clinical trials of negative symptoms in schizophrenia: a meta-regression analysis. Schizophr Bull. 2019;45(1):57\u201368. https:\/\/doi.org\/10.1093\/schbul\/sbx192.","journal-title":"Schizophr Bull"},{"issue":"12","key":"631_CR57","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1001\/jamapsychiatry.2014.1319","volume":"71","author":"BR Rutherford","year":"2014","unstructured":"Rutherford BR, Pott E, Tandler JM, Wall MM, Roose SP, Lieberman JA. Placebo response in antipsychotic clinical trials: a meta-analysis. JAMA Psychiat. 2014;71(12):1409\u201321. https:\/\/doi.org\/10.1001\/jamapsychiatry.2014.1319.","journal-title":"JAMA Psychiat"},{"key":"631_CR58","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/bs.irn.2020.03.029","volume":"153","author":"S Anderson","year":"2020","unstructured":"Anderson S, Stebbins GT. Determinants of placebo effects. Int Rev Neurobiol. 2020;153:27\u201347. https:\/\/doi.org\/10.1016\/bs.irn.2020.03.029.","journal-title":"Int Rev Neurobiol"},{"key":"631_CR59","unstructured":"Food and Drug Administration. Guidance for Industry Systemic Lupus Erythematosus \u2014 Developing Medical Products for Treatment 2010:18. June 2010."},{"key":"631_CR60","unstructured":"Food and Drug Administration. Guideline for Industry The Extent of Population Exposure to Assess Clinical Safety: For Drugs Intended for Longterm Treatment of Non-LifeThreatening Conditions. Vol. ICH-E1A. 1995. March 1995."},{"key":"631_CR61","unstructured":"European Medicines Agency. Guideline on clinical investigation of medicinal products for the treatment of systemic lupus erythematosus and lupus nephritis. 2015:16. February 2015."},{"issue":"1","key":"631_CR62","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jaad.2019.05.102","volume":"82","author":"HH Lee","year":"2020","unstructured":"Lee HH, Patel KR, Rastogi S, et al. Placebo responses in randomized controlled trials for systemic therapy in atopic dermatitis: a systematic review and meta-analysis. J Am Acad Dermatol. 2020;82(1):62\u201371. https:\/\/doi.org\/10.1016\/j.jaad.2019.05.102.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"631_CR63","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1159\/000365248","volume":"61","author":"K Weimer","year":"2015","unstructured":"Weimer K, Colloca L, Enck P. Age and sex as moderators of the placebo response \u2013 an evaluation of systematic reviews and meta-analyses across medicine. Gerontology. 2015;61(2):97\u2013108. https:\/\/doi.org\/10.1159\/000365248.","journal-title":"Gerontology"},{"issue":"4","key":"631_CR64","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s11017-011-9179-8","volume":"32","author":"FG Miller","year":"2011","unstructured":"Miller FG, Colloca L. The placebo phenomenon and medical ethics: rethinking the relationship between informed consent and risk-benefit assessment. Theor Med Bioeth. 2011;32(4):229\u201343. https:\/\/doi.org\/10.1007\/s11017-011-9179-8.","journal-title":"Theor Med Bioeth"},{"issue":"6","key":"631_CR65","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1056\/NEJMra1907805","volume":"382","author":"L Colloca","year":"2020","unstructured":"Colloca L, Barsky AJ. Placebo and nocebo effects. N Engl J Med. 2020;382(6):554\u201361. https:\/\/doi.org\/10.1056\/NEJMra1907805.","journal-title":"N Engl J Med"},{"issue":"10","key":"631_CR66","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.94930","volume":"17","author":"A Forsyth","year":"2025","unstructured":"Forsyth A, Prajapati S, Frasier KM, et al. Diagnostic disparities in erythema visibility: a call to redefine inflammatory assessment in diverse skin tones. Cureus. 2025;17(10):e94930. https:\/\/doi.org\/10.7759\/cureus.94930.","journal-title":"Cureus"},{"issue":"1","key":"631_CR67","first-page":"22","volume":"18","author":"NO Gunowa","year":"2022","unstructured":"Gunowa NO. Skin tone bias and wound care: highlighting the current evidence and addressing the gaps in knowledge of dark skin tones. Wounds UK. 2022;18(1):22\u20137.","journal-title":"Wounds UK"},{"issue":"1","key":"631_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-024-01176-8","volume":"7","author":"VR Weir","year":"2024","unstructured":"Weir VR, Dempsey K, Gichoya JW, Rotemberg V, Wong AI. A survey of skin tone assessment in prospective research. NPJ Digit Med. 2024;7(1):191. https:\/\/doi.org\/10.1038\/s41746-024-01176-8.","journal-title":"NPJ Digit Med"},{"issue":"2","key":"631_CR69","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/bjd.12653","volume":"170","author":"SM Verma","year":"2014","unstructured":"Verma SM, Okawa J, Propert KJ, Werth VP. The impact of skin damage due to cutaneous lupus on quality of life. Br J Dermatol. 2014;170(2):315\u201321. https:\/\/doi.org\/10.1111\/bjd.12653.","journal-title":"Br J Dermatol"},{"issue":"8","key":"631_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13082419","volume":"13","author":"A Fija\u0142kowska","year":"2024","unstructured":"Fija\u0142kowska A, K\u0105dziela M, \u017bebrowska A. The spectrum of cutaneous manifestations in lupus erythematosus: a comprehensive review. J Clin Med. 2024;13(8):2419.","journal-title":"J Clin Med"},{"issue":"1","key":"631_CR71","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/acr.23578","volume":"71","author":"C Drenkard","year":"2019","unstructured":"Drenkard C, Parker S, Aspey LD, et al. Racial disparities in the incidence of primary chronic cutaneous lupus erythematosus in the Southeastern US: the Georgia Lupus Registry. Arthritis Care Res (Hoboken). 2019;71(1):95\u2013103. https:\/\/doi.org\/10.1002\/acr.23578.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"631_CR72","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2019-000344","volume":"6","author":"P Izmirly","year":"2019","unstructured":"Izmirly P, Buyon J, Belmont HM, et al. Population-based prevalence and incidence estimates of primary discoid lupus erythematosus from the Manhattan Lupus Surveillance Program. Lupus Sci Med. 2019;6(1):e000344. https:\/\/doi.org\/10.1136\/lupus-2019-000344.","journal-title":"Lupus Sci Med"},{"issue":"6","key":"631_CR73","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.jaad.2007.08.008","volume":"57","author":"J Hick","year":"2007","unstructured":"Hick J, Feldman SR. Eligibility creep: A cause for placebo group improvement in controlled trials of psoriasis treatments. J Am Acad Dermatol. 2007;57(6):972\u20136. https:\/\/doi.org\/10.1016\/j.jaad.2007.08.008.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"631_CR74","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1093\/ced\/llad162","volume":"48","author":"C Gan","year":"2023","unstructured":"Gan C, Mahil S, Pink A, Rodrigues M. Atopic dermatitis in skin of colour. Part 2: considerations in clinical presentation and treatment options. Clin Exp Dermatol. 2023;48(10):1091\u2013101. https:\/\/doi.org\/10.1093\/ced\/llad162.","journal-title":"Clin Exp Dermatol"},{"key":"631_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.916134","volume":"9","author":"AM Walker","year":"2022","unstructured":"Walker AM, Lu G, Clifton SC, Ogunsanya ME, Chong BF. Influence of socio-demographic factors in patients with cutaneous lupus erythematosus. Front Med (Lausanne). 2022;9:916134. https:\/\/doi.org\/10.3389\/fmed.2022.916134.","journal-title":"Front Med (Lausanne)."},{"issue":"10541","key":"631_CR76","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1016\/s0140-6736(26)00463-0","volume":"407","author":"EF Morand","year":"2026","unstructured":"Morand EF, Dall\u2019Era M, Sanchez-Guerrero J, et al. Enpatoran, a Toll-like receptor 7\/8 inhibitor, in moderate-to-severe systemic lupus erythematosus: findings from Cohort B of a multicentre, international, double-blind, placebo-controlled dose-finding phase 2 trial. Lancet. 2026;407(10541):1809\u201324. https:\/\/doi.org\/10.1016\/s0140-6736(26)00463-0.","journal-title":"Lancet"}],"container-title":["Pharmaceutical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-026-00631-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40290-026-00631-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-026-00631-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:22:41Z","timestamp":1788495761000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40290-026-00631-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":76,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["631"],"URL":"https:\/\/doi.org\/10.1007\/s40290-026-00631-z","relation":{},"ISSN":["1178-2595","1179-1993"],"issn-type":[{"value":"1178-2595","type":"print"},{"value":"1179-1993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"assertion":[{"value":"28 July 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors are employed by Indero\u00a0(formerly Innovaderm Research). Dr Jasmina Jankicevic is also a Consultant for CSA BioTech, RAPT Therapeutics, and SROne. Dr Robert Bissonnette is an Advisory Board Member, Consultant, Speaker, and\/or Investigator for and receives honoraria and\/or grant from AbbVie, Aclaris, Almirall, Alumis, Amgen, Apogee, Arcutis, Areteia, Artax, Attovia, BioMimetix, Bluefin, CARA Therapeutics, Clexio, Eli Lilly, Escient, Fresh Tracks (Brickell), Incyte, Inmagene Bio, J&J (Janssen), LEO Pharma, Merck, Opsidio, Organon (Dermavant), Pfizer, Q32, RAPT Therapeutics, Sanofi Genzyme, Sanofi Aventis, Sitryx, Target RWE, Triveni, Xencor and Zurabio. Dr Robert Bissonnette is also a shareholder of Indero (formerly Innovaderm Research).","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors contributed to the study conception and design. The literature search was performed by St\u00e9phanie L\u00e9gar\u00e9. Screening of records and assessment of full texts for eligibility were performed by St\u00e9phanie L\u00e9gar\u00e9 and Sherry Lin. Data extraction was performed by St\u00e9phanie L\u00e9gar\u00e9 and Sherry Lin. Verification of data extracted was performed by St\u00e9phanie L\u00e9gar\u00e9, Sherry Lin, and Sarah Vahey. Statistical analyses were performed by Sarah Vahey. The first draft of the manuscript was written by St\u00e9phanie L\u00e9gar\u00e9 and all authors commented on previous versions of the manuscript. All authors read and approved the final submitted manuscript and agreed to be accountable for the work.","order":2,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All relevant data are provided within the manuscript and supporting files.","order":3,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}